Sponsors should not strive to repeat the success of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy treatment Exondys 51, FDA's Office of New Drugs Director John Jenkins warned.
Jenkins said the Exondys 51 (eteplirsen) development program, which received an accelerated approval from FDA despite opposition from him and several others
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?